Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i5.10
pages 389-418

CD28/B7 Costimulation: A Review

Edward A. Greenfield
Department Of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115. Center For Neurological Diseases, Brigham and Women's Hospital, Boston, MA 02115
Khuong A. Nguyen
Department Of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115
Vijay K. Kuchroo
Center For Neurological Diseases, Brigham and Women's Hospital, Boston, MA 02115

Краткое описание

The current model of T cell activation requires two signals. The first signal is specific, requiring T cell receptor recognition and binding to MHC/Antigen presented by an antigen-presenting cell. The second signal is nonspecific, resulting from the binding of B7 ligand on the antigen-presenting cell with its receptor, CD28, on the T cell. If both signals are provided, the T cell will proliferate and secrete cytokines. Recently, it has been shown that CTLA4, another receptor for B7 that is upregulated following T cell after activation, can deliver an inhibitory signal, downregulating T cell proliferation. The B7 family of ligands has two family members, B7-1 and B7-2. They both bind to CD28 and CTLA4, but they differ in their binding affinity, structure, and temporal expression. Considerable research has been done on the CD28/B7 costimulatory pathway. Different ways of manipulating this pathway could provide insights into the mechanism and treatment of opposing pathological states. Blocking the CD28/B7 pathway could result in immunosuppression, with implications for the treatment of autoimmune diseases, organ transplantation, and graft vs. host disease. Activating the CD28/B7 pathway could be useful for including the immune system to recognize and eliminate tumors that evade the immune system. Finally, the CD28/B7 pathway could be involved with maintaining immune tolerance, as recent studies suggest the preferential binding of the B7-CTLA4 pathway results in the down-regulation of the responding T cells. Thus, the B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses.

Ключевые слова: costimulation, CD28, B7, CTLA4.

Articles with similar content:

Signal Integration Following Toll-like Receptor Triggering
Critical Reviews™ in Immunology, Vol.22, 2002, issue 3
Alexander Dalpke, Klaus Heeg
Linkage of Immune Self-Tolerance with the Positive Selection of T Cells
Critical Reviews™ in Immunology, Vol.19, 1999, issue 3
Robert L. Rubin, Anke Kretz-Rommel
Role for the cAMP-Protein Kinase A Signaling Pathway in Suppression of Antitumor Immune Responses by Regulatory T Cells
Critical Reviews™ in Oncogenesis, Vol.14, 2008, issue 1
Kjetil Tasken, Sheraz Yaqub
Functions of CD40 and Its Ligand, gp39 (CD40L)
Critical Reviews™ in Immunology, Vol.16, 1996, issue 1
Jon D. Laman, Randolph J. Noelle, Eric Claassen
Naturally Occurring Regulatory T Cells: Recent Insights in Health and Disease
Critical Reviews™ in Immunology, Vol.27, 2007, issue 1
Penelope A. Morel, Giorgio Raimondi, Michael S. Turner, Angus W. Thomson